Next Generation Neuromuscular Detection

Digital Biomarker Platform for Parkinson's

Early detection and real-time therapeutic monitoring through IMU-observed daily life gait analysis. Better data, better care.

Clinical Lab Limitations

Traditional testing is restricted to optimal lab conditions, missing crucial daily real-life movement patterns.

The Cost Barrier

Expensive PET/DAT scans are not scalable for continuous, early detection of neuromuscular disorders.

Unconstrained Assessment

Using wearable IMUs on the wrist and ankle allows for home-based, comfortable monitoring throughout the day.

Longitudinal Data

Capture micro-tremors and subtle gait asymmetry years before visible brain damage occurs.

Real-time AI Processing

Custom IoT pipeline feeds data directly to an AI server, using our 1D CNN model (92% precision) for risk prediction.

Therapeutic Monitoring

Quantify tremor reduction and gait improvement before and after Levodopa to adjust dose timing accurately.

Our Founders

The Minds Behind Vancure

Developing state-of-the-art technology for early Parkinson's detection and therapeutic monitoring.

Takuto Ishijima

CEO

Leading the overall company vision, global business strategy, and executive leadership at Vancure.

LeadershipBusiness StrategyExecution

Anushtup Ghosh

CTO

Driving the vision and technical architecture behind Vancure's AI and hardware integration. Leading the research on micro-tremor detection algorithms.

AI ArchitectureSignal ProcessingStrategy

Pradipta Kumar Paria

COO

Spearheading the custom wearable hardware development and sensor fusion algorithms. Specialist in low-power embedded systems for continuous monitoring.

Hardware DesignEmbedded C++Robotics

Coming Soon

The Vancure App
Is Almost Here.

Real-time motor symptom monitoring, medication tracking, and seamless clinician data sharing — all from your phone. Sign up to be the first to know when we launch.

Coming to

App Store